| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2013PNAS..11019095K |
| P356 | DOI | 10.1073/PNAS.1315860110 |
| P932 | PMC publication ID | 3839782 |
| P698 | PubMed publication ID | 24191058 |
| P50 | author | Mercedes Monteleone | Q57371844 |
| Sabine Ehrt | Q61189875 | ||
| Dirk Schnappinger | Q88475126 | ||
| Kyu Y Rhee | Q93195831 | ||
| Clifton E Barry | Q51118358 | ||
| P2093 | author name string | Helena I M Boshoff | |
| Daniel J Wilson | |||
| Courtney C Aldrich | |||
| Ritu Sharma | |||
| Jee-Hyun Kim | |||
| Sumit Chakraborty | |||
| Joshua B Wallach | |||
| Kathryn M O'Brien | |||
| German Rehren | |||
| P2860 | cites work | High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism | Q21131409 |
| Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties | Q24674719 | ||
| Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor | Q24802513 | ||
| Identification, characterization, and crystal structure of Bacillus subtilis nicotinic acid mononucleotide adenylyltransferase | Q27636152 | ||
| Engineering controllable protein degradation. | Q51184362 | ||
| Simultaneous analysis of multiple Mycobacterium tuberculosis knockdown mutants in vitro and in vivo | Q28476622 | ||
| Evaluating the sensitivity of Mycobacterium tuberculosis to biotin deprivation using regulated gene expression | Q28477282 | ||
| High-throughput screening and sensitized bacteria identify an M. tuberculosis dihydrofolate reductase inhibitor with whole cell activity | Q28480878 | ||
| Global assessment of genomic regions required for growth in Mycobacterium tuberculosis | Q28484097 | ||
| 4'-Phosphopantetheinyl transferase PptT, a new drug target required for Mycobacterium tuberculosis growth and persistence in vivo | Q28484764 | ||
| Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli | Q28487010 | ||
| Identification of the Escherichia coli nicotinic acid mononucleotide adenylyltransferase gene | Q28611177 | ||
| In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice | Q28909142 | ||
| Drugs for bad bugs: confronting the challenges of antibacterial discovery | Q29547723 | ||
| Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates | Q29618010 | ||
| The spectrum of latent tuberculosis: rethinking the biology and intervention strategies | Q29619404 | ||
| Persister cells | Q30018300 | ||
| The Sir 2 family of protein deacetylases | Q33222287 | ||
| Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis | Q33826465 | ||
| Bacterial DNA ligases. | Q33953479 | ||
| Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection | Q34006776 | ||
| NAD+ auxotrophy is bacteriocidal for the tubercle bacilli | Q34155799 | ||
| ClpXP, an ATP-powered unfolding and protein-degradation machine | Q34198403 | ||
| Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening | Q34355038 | ||
| Depletion of antibiotic targets has widely varying effects on growth | Q34651942 | ||
| Protein inactivation in mycobacteria by controlled proteolysis and its application to deplete the beta subunit of RNA polymerase. | Q34723636 | ||
| Gene regulation by tetracyclines. Constraints of resistance regulation in bacteria shape TetR for application in eukaryotes | Q35180176 | ||
| Confronting the scientific obstacles to global control of tuberculosis | Q36513366 | ||
| A subsystems-based approach to the identification of drug targets in bacterial pathogens. | Q36695075 | ||
| Microbial phenotypic heterogeneity and antibiotic tolerance. | Q36704124 | ||
| The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis | Q36954404 | ||
| Improved tetracycline repressors for gene silencing in mycobacteria | Q37149754 | ||
| The Influence of Adverse Conditions upon the Respiratory Metabolism and Growth of Human Tubercle Bacilli | Q37678699 | ||
| Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. | Q37860758 | ||
| New tuberculosis drugs on the horizon | Q37912808 | ||
| Salmonella persistence and transmission strategies | Q37964243 | ||
| Engineered Tet repressors with recognition specificity for the tetO-4C5G operator variant | Q38297444 | ||
| Single-chain Tet transregulators | Q39778017 | ||
| Identifying vulnerable pathways in Mycobacterium tuberculosis by using a knockdown approach | Q41849520 | ||
| Inhibition of the sole type I signal peptidase of Mycobacterium tuberculosis is bactericidal under replicating and nonreplicating conditions | Q42152549 | ||
| Functional comparison of the NAD binding cleft of ADP-ribosylating toxins | Q42629538 | ||
| P433 | issue | 47 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 19095-19100 | |
| P577 | publication date | 2013-11-04 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence | |
| P478 | volume | 110 |
| Q57483511 | A Lysine Acetyltransferase Contributes to the Metabolic Adaptation to Hypoxia in Mycobacterium tuberculosis |
| Q63370369 | An NAD Phosphorylase Toxin Triggers Mycobacterium tuberculosis Cell Death |
| Q47753815 | Antibacterial drugs: Persisters come under fire |
| Q44222401 | Antimicrobials: persisters come under fire |
| Q38973157 | Assessing essentiality of transketolase in Mycobacterium tuberculosis using an inducible protein degradation system |
| Q40793029 | Cloning, expression and characterization of histidine-tagged biotin synthase of Mycobacterium tuberculosis. |
| Q40854279 | Cloning, expression, purification, crystallization and preliminary X-ray diffraction studies of NAD synthetase from methicillin-resistant Staphylococcus aureus |
| Q53290093 | Construction of conditional knockdown mutants in mycobacteria. |
| Q47625498 | Control of biotin biosynthesis in mycobacteria by a pyruvate carboxylase dependent metabolic signal |
| Q47928358 | Cooperative development of antimicrobials: looking back to look ahead |
| Q60949745 | Demethylmenaquinone Methyl Transferase Is a Membrane Domain-Associated Protein Essential for Menaquinone Homeostasis in |
| Q37736367 | Depleting Mycobacterium tuberculosis of the transcription termination factor Rho causes pervasive transcription and rapid death |
| Q90133826 | Derailing the aspartate pathway of Mycobacterium tuberculosis to eradicate persistent infection |
| Q38615638 | Design, synthesis, and evaluation of substituted nicotinamide adenine dinucleotide (NAD(+)) synthetase inhibitors as potential antitubercular agents |
| Q41825213 | Detection of Mycobacterium tuberculosis in latently infected lungs by immunohistochemistry and confocal microscopy |
| Q49968014 | Drug targets in dormant Mycobacterium tuberculosis: can the conquest against tuberculosis become a reality? |
| Q41927049 | Enabling faster Go/No-Go decisions through secondary screens in anti-mycobacterial drug discovery |
| Q40324975 | Fumarase Deficiency Causes Protein and Metabolite Succination and Intoxicates Mycobacterium tuberculosis |
| Q52579183 | Gene Enrichment Analysis Reveals Major Regulators of Mycobacterium tuberculosis Gene Expression in Two Models of Antibiotic Tolerance. |
| Q35795582 | Genetic Approaches to Facilitate Antibacterial Drug Development |
| Q40306037 | Glyoxylate detoxification is an essential function of malate synthase required for carbon assimilation in Mycobacterium tuberculosis |
| Q47702665 | Hit Generation in TB Drug Discovery: From Genome to Granuloma |
| Q34374612 | Identification of plant-derived natural products as potential inhibitors of the Mycobacterium tuberculosis proteasome |
| Q28539080 | Inactivation of fructose-1,6-bisphosphate aldolase prevents optimal co-catabolism of glycolytic and gluconeogenic carbon substrates in Mycobacterium tuberculosis |
| Q37336948 | Investigating essential gene function in Mycobacterium tuberculosis using an efficient CRISPR interference system. |
| Q92886011 | Large-scale chemical-genetics yields new M. tuberculosis inhibitor classes |
| Q30398195 | Metabolic Perspectives on Persistence |
| Q54228837 | Metabolic principles of persistence and pathogenicity in Mycobacterium tuberculosis. |
| Q28083739 | Mycobacterial genes essential for the pathogen's survival in the host |
| Q35199412 | Mycobacterial nicotinate mononucleotide adenylyltransferase: structure, mechanism, and implications for drug discovery |
| Q55380367 | Mycobacterium tuberculosis Pst/SenX3-RegX3 Regulates Membrane Vesicle Production Independently of ESX-5 Activity. |
| Q28552573 | Mycobacterium tuberculosis Thioredoxin Reductase Is Essential for Thiol Redox Homeostasis but Plays a Minor Role in Antioxidant Defense |
| Q39361724 | Mycobacterium tuberculosis in the Face of Host-Imposed Nutrient Limitation |
| Q35245286 | Mycobacterium tuberculosis metabolism |
| Q28388477 | New insights into TB physiology suggest untapped therapeutic opportunities |
| Q60303471 | ORBIT: a New Paradigm for Genetic Engineering of Mycobacterial Chromosomes |
| Q83227366 | Persistent infection in mice requires PerM for successful cell division |
| Q38252559 | Pharmacologic considerations in use and development of antituberculosis drugs |
| Q38508448 | Phenotypic Heterogeneity, a Phenomenon That May Explain Why Quorum Sensing Does Not Always Result in Truly Homogenous Cell Behavior |
| Q91044969 | Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development |
| Q38258837 | Production of recombinant proteins in Mycobacterium smegmatis for structural and functional studies |
| Q42517549 | Promoter mutagenesis for fine-tuning expression of essential genes in Mycobacterium tuberculosis |
| Q41596967 | Resuscitation-promoting factors are cell wall-lytic enzymes with important roles in the germination and growth of Streptomyces coelicolor |
| Q38828644 | Strategies of genome editing in mycobacteria: Achievements and challenges |
| Q42065966 | Systems level mapping of metabolic complexity in Mycobacterium tuberculosis to identify high-value drug targets |
| Q39149038 | Targeting Phenotypically Tolerant Mycobacterium tuberculosis |
| Q52562988 | Targeting protein biotinylation enhances tuberculosis chemotherapy. |
| Q49488769 | The Methylerythritol Phosphate Pathway: Promising Drug Targets in the Fight against Tuberculosis. |
| Q26795478 | The application of tetracyclineregulated gene expression systems in the validation of novel drug targets in Mycobacterium tuberculosis |
| Q37203793 | Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3 |
| Q89635890 | Tissue distribution of doxycycline in animal models of tuberculosis |
| Q28554966 | Trehalose-6-Phosphate-Mediated Toxicity Determines Essentiality of OtsB2 in Mycobacterium tuberculosis In Vitro and in Mice |
| Q28390218 | Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool |
| Q47159580 | Tuberculosis: Just the FAQs |
| Q91947033 | Utility of OhrR-Ohr system for the expression of recombinant proteins in mycobacteria and for the delivery of M. tuberculosis antigens to the phagosomal compartment |
| Q92500165 | Utilization of CRISPR Interference To Validate MmpL3 as a Drug Target in Mycobacterium tuberculosis |
| Q37497737 | Validation of CoaBC as a Bactericidal Target in the Coenzyme A Pathway of Mycobacterium tuberculosis |
Search more.